Urologix signs deal to sell Prostiva RF therapy system for BPH

Urologix ($ULGX) has inked an exclusive worldwide license for the Prostiva RF therapy system from Medtronic ($MDT). The system is a transurethral needle ablation device that is 510(k) cleared for the treatment of BPH. The license agreement is for a 10-year term and includes the rights to manufacture and market the Prostiva product line for an upfront license fee and ongoing royalties. Urologix release

Suggested Articles

The U.S. regulator has given the green light to moderate-risk medical devices despite them not always meeting the FDA’s own standards.

Machine learning drug development company insitro has bought up Haystack Sciences, adding DNA-encoded libraries to its R&D arsenal.

IBM and Pfizer developed an artificial intelligence model that could eventually predict if a person will develop Alzheimer’s using a language test.